Skip to content

Study · Not a test of the peptide alone · 2015

3 results

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.

Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA

Diabetes, obesity & metabolism7 Jan 2015Cited by 159 (Europe PMC)

PMID25425451 (opens in a new tab)PMCIDPMC5577982 (opens in a new tab)DOI10.1111/dom.12417 (opens in a new tab)PepBankPUB-25425451
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In newly diagnosed T2DM, metformin/pioglitazone/exenatide reduced HbA1c more than conventional therapy.

    In plain wordsIn newly diagnosed diabetes, metformin/pioglitazone/exenatide reduced HbA1c more than sequential conventional therapy.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c
    Study

    n = 221

    Comparator
    sequential metformin, sulfonylurea and glargine insulin
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    5.95%
    triple therapy
    HbA1c
    6.5%
    conventional therapy

    Source sentences

    Summary
    Participants receiving triple therapy experienced a significantly greater reduction in HbA1c level than those receiving conventional therapy (5.95 vs. 6.50%; p < 0.001).
    1 context sentence
    Summary · context
    Drug-naïve, recently diagnosed subjects with type 2 diabetes mellitus (T2DM) were randomized in an open-fashion design in a single-centre study to metformin/pioglitazone/exenatide (triple therapy; n = 106) or an escalating dose of metformin followed by sequential addition of sulfonylurea and glargin…

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome

    In newly diagnosed T2DM, metformin/pioglitazone/exenatide had a lower hypoglycaemia rate than conventional therapy.

    In plain wordsIn newly diagnosed diabetes, metformin/pioglitazone/exenatide caused fewer low blood sugar events than conventional therapy.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHypoglycaemia rate
    Study

    n = 221

    Comparator
    sequential metformin, sulfonylurea and glargine insulin
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    lower hypoglycaemia rate
    7.5 fold
    triple versus conventional therapy

    Source sentences

    Summary
    Despite lower HbA1c values, participants receiving triple therapy experienced a 7.5-fold lower rate of hypoglycaemia compared with participants receiving conventional therapy.
    1 context sentence
    Summary · context
    Drug-naïve, recently diagnosed subjects with type 2 diabetes mellitus (T2DM) were randomized in an open-fashion design in a single-centre study to metformin/pioglitazone/exenatide (triple therapy; n = 106) or an escalating dose of metformin followed by sequential addition of sulfonylurea and glargin…

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In newly diagnosed T2DM, metformin/pioglitazone/exenatide produced weight loss versus weight gain with conventional therapy.

    In plain wordsIn newly diagnosed diabetes, metformin/pioglitazone/exenatide reduced weight compared with weight gain on conventional therapy.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 221

    Comparator
    sequential metformin, sulfonylurea and glargine insulin
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    weight loss
    1.2 kg
    triple therapy
    weight gain
    4.1 kg
    conventional therapy

    Source sentences

    Summary
    Participants receiving triple therapy experienced a mean weight loss of 1.2 kg versus a mean weight gain of 4.1 kg (p < 0.01) in those receiving conventional therapy.
    1 context sentence
    Summary · context
    Drug-naïve, recently diagnosed subjects with type 2 diabetes mellitus (T2DM) were randomized in an open-fashion design in a single-centre study to metformin/pioglitazone/exenatide (triple therapy; n = 106) or an escalating dose of metformin followed by sequential addition of sulfonylurea and glargin…

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.